<span item_type="fundamental" item_id="6661b968b1c1aca54ff0cfa9d6e98172" counter_id="ST/US/ERNA" env="prod"></span><span item_type="announcement" item_id="580266468111621761" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.15.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -1.265 M.</p><p></p><h3>Segment Revenue</h3><ul><li>No revenue was generated for the three and nine months ended September 30, 2025, compared to $487,000 and $581,000 for the same periods in 2024, respectively.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/748592/000149315225021287/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The net loss for the three months ended September 30, 2025, was $1.2 million, a significant improvement from the $26.6 million loss in the same period in 2024. For the nine months ended September 30, 2025, the net loss was $12.6 million, compared to $38.8 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/748592/000149315225021287/form10-q.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses decreased to $1.993 million for the three months ended September 30, 2025, from $2.806 million in 2024. For the nine months ended September 30, 2025, operating expenses were $7.225 million, down from $13.462 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/748592/000149315225021287/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used in operating activities was $5.9 million for the nine months ended September 30, 2025, compared to $12.3 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/748592/000149315225021287/form10-q.htm"></span></li><li><strong>Free Cash Flow</strong>: Not explicitly stated, but the net increase in cash and cash equivalents was $1.318 million for the nine months ended September 30, 2025, compared to a decrease of $7.406 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/748592/000149315225021287/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Forward Sales Contract Expense</strong>: A non-cash expense of $5.8 million was recognized in the nine months ended September 30, 2025, related to a forward sales contract.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/748592/000149315225021287/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Ernexa Therapeutics Inc. plans to complete IND enabling studies and submit an IND for ERNA-101 by 2026, with a Phase I clinical trial expected in the same year. The company is also investigating ERNA-201 for autoimmune disorders.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/748592/000149315225021287/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is seeking strategic partnerships to co-develop or out-license therapeutic assets and is applying for research grants to support its operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/748592/000149315225021287/form10-q.htm"></span></li><li><strong>Priority</strong>: The company emphasizes the need to raise additional capital to fund operations beyond the next 12 months, with no current arrangements for capital in place.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/748592/000149315225021287/form10-q.htm"></span></li></ul>

Ernexa Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0